We showed that similar to Usp9x KD (Figure 2E), G9 treatment also decreased SOX2 levels in BRAF-mutant melanoma cells and MG132 treatment reversed the reduction of SOX2 by G9 (Supplementary Figure 2B bottom). This evidence concerns the gene BRAF and melanoma.